Satoh S, Watanabe J, Keitoku M, Kinoshita H, Sekiguchi N, Endoh S, Ohtsuka K, Hangai K, Morita M, Takishima T
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Arzneimittelforschung. 1989 Aug;39(8):908-11.
The purpose of this study was to examine the effects of N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a newly developed antiarrhythmic agent belonging to class Ic, on the ventriculoatrial (VA) conductivity of accessory pathways and paroxysmal supra-ventricular tachycardia (PSVT). Twelve patients with accessory pathways were examined by standard electrophysiologic technique before and after a single oral dose of SUN 1165 (100 mg). 1 h after administration, SUN 1165 blocked VA conduction of the accessory pathway in six of twelve patients and prevented the induction of PSVT in six of seven cases. In the cases in which VA block did not occur, the VA interval prolonged (from 178 +/- 7 to 190 +/- 11 ms, p less than 0.05), and the effective refractory period of VA conduction was also increased (from 273 +/- 10 to 318 +/- 15 ms. p less than 0.05). SUN 1165 also prolonged the conduction time in normal conduction systems (AH and HV intervals and QRS duration), but the degree of the prolongation was moderate and not dangerous. There was no adverse effect. These results indicate that SUN 1165 is a potent and safe antiarrhythmic agent, and useful for preventing or stopping PSVT by blocking or depressing VA conduction through accessory pathways.
本研究旨在探讨新型Ic类抗心律失常药物盐酸N-(2,6-二甲基苯基)-8-吡咯烷乙酰胺半水合物(SUN 1165)对旁路房室(VA)传导及阵发性室上性心动过速(PSVT)的影响。采用标准电生理技术,对12例有旁路的患者在单次口服SUN 1165(100 mg)前后进行检查。给药1小时后,SUN 1165使12例患者中的6例旁路VA传导阻滞,并使7例患者中的6例PSVT诱发受阻。在未发生VA阻滞的病例中,VA间期延长(从178±7毫秒延长至190±11毫秒,p<0.05),VA传导的有效不应期也增加(从273±10毫秒增至318±15毫秒,p<0.05)。SUN 1165还延长了正常传导系统的传导时间(AH和HV间期以及QRS时限),但延长程度适中且无危险性。未出现不良反应。这些结果表明,SUN 1165是一种强效且安全的抗心律失常药物,可通过阻断或抑制经旁路的VA传导来预防或终止PSVT。